Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Add a description, image, and links to the javascript-2 topic page so that developers can more easily learn about it.

Chinese startup Beijing Moonshot AI Co. Ltd. Thursday released a new open-source artificial intelligence model, named Kimi 2 Thinking, that displays significantly upgraded tool use and agentic ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...